Accelerated Pharma, which is developing a chemotherapy optimized by genomic screening, withdrew its plans for an initial public offering on Wednesday. It had filed to raise $8 million by offering 1.5 million units at a price range of $4 to $6.
The Westport, CT-based company was founded in 2014 and had planned to list on the Nasdaq under the symbol ACCP. Rodman & Renshaw and Joseph Gunnar were set to be the joint bookrunners on the deal.
